CTSO Cytosorbents Corporation Stock Quote

CTSO [NASD]

Index	-	P/E	-	EPS (ttm)	-0.32	Insider Own	1.20%	Shs Outstand	41.59M	Perf Week	2.08%
Market Cap	414.51M	Forward P/E	-	EPS next Y	-0.15	Insider Trans	-1.48%	Shs Float	39.55M	Perf Month	10.14%
Income	-11.10M	PEG	-	EPS next Q	-0.04	Inst Own	40.70%	Short Float	7.63%	Perf Quarter	11.59%
Sales	36.50M	P/S	11.36	EPS this Y	-6.60%	Inst Trans	0.19%	Short Ratio	10.45	Perf Half Y	-7.16%
Book/sh	1.93	P/B	4.84	EPS next Y	34.80%	ROA	-19.70%	Target Price	14.88	Perf Year	102.60%
Cash/sh	1.98	P/C	4.71	EPS next 5Y	-	ROE	-34.40%	52W Range	3.60 - 11.74	Perf YTD	17.19%
Dividend	-	P/FCF	-	EPS past 5Y	14.30%	ROI	-96.70%	52W High	-20.44%	Beta	0.18
Dividend %	-	Quick Ratio	5.50	Sales past 5Y	43.30%	Gross Margin	70.90%	52W Low	159.44%	ATR	0.40
Employees	156	Current Ratio	5.60	Sales Q/Q	72.10%	Oper. Margin	-36.30%	RSI (14)	61.79	Volatility	4.95% 4.38%
Optionable	Yes	Debt/Eq	0.19	EPS Q/Q	90.50%	Profit Margin	-30.50%	Rel Volume	0.74	Prev Close	9.21
Shortable	Yes	LT Debt/Eq	0.07	Earnings	Nov 04 AMC	Payout	-	Avg Volume	288.68K	Price	9.34
Recom	1.70	SMA20	8.88%	SMA50	9.70%	SMA200	5.24%	Volume	215,678	Change	1.41%

Sep-17-20

Initiated

Jefferies

Buy

$15

Sep-01-20

Initiated

SVB Leerink

Outperform

$15

Aug-08-17

Reiterated

Maxim Group

Buy

$10 → $12

Oct-26-16

Initiated

Aegis Capital

Buy

May-24-16

Initiated

Maxim Group

Buy

Oct-29-15

Upgrade

WBB Securities

Speculative Buy → Buy

$13 → $13

May-12-15

Reiterated

MLV & Co

Buy

$28 → $21

Apr-01-15

Reiterated

MLV & Co

Buy

$28 → $30

Mar-05-15

Initiated

MLV & Co

Buy

$30

Feb-25-15

Initiated

WBB Securities

Speculative Buy

$13

Jan-27-15

Reiterated

H.C. Wainwright

Buy

$1 → $12

Jan-21-21 07:08AM	CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President - Global Regulatory Affairs PR Newswire
Jan-19-21 07:08AM	CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care PR Newswire
Jan-12-21 07:00AM	Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients PR Newswire
07:00AM	Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients CNW Group
06:58AM	CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue PR Newswire
Jan-11-21 06:00AM	CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing PR Newswire
Jan-04-21 06:30AM	Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients PR Newswire +5.02%
Dec-17-20 07:08AM	CytoSorbents Promotes Dr. Christian Steiner to Executive Vice President of Sales and Marketing PR Newswire
Dec-13-20 09:44PM	Is CTSO A Good Stock To Buy Now? Insider Monkey
Dec-10-20 07:00AM	CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank PR Newswire
Dec-09-20 06:45AM	Early CytoSorb Initiation Improves Hemodynamic Stabilization and Survival in New Septic Shock Study PR Newswire
Dec-02-20 07:08AM	CytoSorbents Launches International Campaign to Raise $100,000 for the Global Humanitarian Organization, CARE PR Newswire
Nov-25-20 07:08AM	CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients PR Newswire
Nov-23-20 07:00AM	CytoSorbents to Present at the Piper Sandler 32nd Annual Healthcare Conference PR Newswire
Nov-12-20 02:00AM	CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference PR Newswire
Nov-10-20 05:25AM	CTSO: Strengthened Balance Sheet Supports Growth Initiatives As Demand For CytoSorb Continues to Surge Zacks Small Cap Research
Nov-06-20 06:05AM	Cytosorbents Corporation (NASDAQ:CTSO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates Simply Wall St.
Nov-04-20 08:31PM	Cytosorbents Corp (CTSO) Q3 2020 Earnings Call Transcript Motley Fool
04:48PM	CytoSorbents: Q3 Earnings Insights Benzinga
04:15PM	CytoSorbents Reports Record Third Quarter 2020 Financial Results PR Newswire
02:45PM	CytoSorbents Corp. to Host Earnings Call ACCESSWIRE
Nov-03-20 10:08AM	Earnings Outlook for CytoSorbents Benzinga +7.21%
Oct-21-20 07:08AM	CytoSorbents to Report Q3 2020 Operating and Financial Results PR Newswire
Oct-14-20 07:00AM	CytoSorbents and Aferetica Announce European Union Approval of the PerLife System and ECOS-300CY PerSorb Cartridge for Combined Perfusion and Purification of Solid Organs Dedicated to Transplant PR Newswire
Oct-09-20 07:08AM	The U.S. Department of Defense Awards $1.1 Million to CytoSorbents to Optimize Development of HemoDefend-BGA for Life-saving Universal Plasma PR Newswire
Sep-21-20 07:08AM	CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other Conditions PR Newswire
Sep-19-20 10:45AM	Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near? Simply Wall St.
Sep-11-20 08:00AM	CytoSorbents Highlights CytoSorb Use in Sepsis Patients During Sepsis Awareness Month and World Sepsis Day 2020 PR Newswire
Sep-08-20 07:08AM	CytoSorbents Announces the "CytoSorb Therapy in COVID-19 ICU Patients" (CTC) Registry Is Actively Enrolling PR Newswire
Sep-01-20 04:50PM	LD Micro:- 360 Companies-- Set to Present this Week. ACCESSWIRE
09:47AM	Benzinga's Top Upgrades, Downgrades For September 1, 2020 Benzinga
Aug-24-20 07:00AM	Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19 PR Newswire
Aug-17-20 07:08AM	CytoSorbents Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under FDA Emergency Use Authorization for COVID-19 PR Newswire
Aug-06-20 09:05AM	CTSO: 2Q20 Results Illustrate Surging Demand For CytoSorb Zacks Small Cap Research
Aug-05-20 09:01AM	Cytosorbents Corp (CTSO) Q2 2020 Earnings Call Transcript Motley Fool
Aug-04-20 05:18PM	Recap: CytoSorbents Q2 Earnings Benzinga
04:15PM	CytoSorbents Reports Record Second Quarter 2020 Financial Results PR Newswire
Aug-03-20 12:47PM	Earnings Outlook for CytoSorbents Benzinga
07:00AM	CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date PR Newswire
Jul-31-20 07:08AM	CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development PR Newswire
Jul-28-20 07:08AM	CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data PR Newswire
06:00AM	CytoSorbents to Report Q2 2020 Operating and Financial Results PR Newswire
Jul-22-20 12:31PM	Why CytoSorbents Is Soaring 12% Today Motley Fool +5.56%
07:22AM	CytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common Stock PR Newswire
Jul-21-20 03:48PM	Why CytoSorbents Stock Got Clobbered Today Motley Fool -17.45%
07:15AM	Is Cytosorbents' (NASDAQ:CTSO) Share Price Gain Of 133% Well Earned? Simply Wall St.
Jul-20-20 04:51PM	CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update PR Newswire
04:26PM	CytoSorbents Corporation Announces Proposed $40 Million Public Offering of Common Stock PR Newswire
Jul-08-20 07:00AM	/C O R R E C T I O N -- CytoSorbents Corporation/ PR Newswire
Jun-29-20 07:08AM	CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding PR Newswire
Jun-25-20 12:27PM	Hedge Funds Have Never Been More Bullish On Cytosorbents Corp (CTSO) Insider Monkey
Jun-24-20 07:30AM	CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise PR Newswire
Jun-19-20 05:40AM	CTSO: Positive Implications of $2.9 Million STTR Phase III Contract Zacks Small Cap Research
Jun-09-20 07:08AM	CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials PR Newswire
Jun-06-20 08:05AM	Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt? Simply Wall St.
May-27-20 12:00PM	CytoSorbents Announces Virtual Annual Meeting PR Newswire -7.56%
May-19-20 08:03AM	CTSO: Q1 2020: CTSO Nabs FDA breakthrough designation and European approval for ticagrelor removal, Q1 Product revenue sets new record, Moving PT to $15/share Zacks Small Cap Research
May-12-20 07:08AM	CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery PR Newswire
May-08-20 02:24PM	The Charts of Cytosorbents Suggest We Might See Further Gains Ahead TheStreet.com
May-06-20 03:01PM	Cytosorbents Corp (CTSO) Q1 2020 Earnings Call Transcript Motley Fool +12.24%
May-05-20 04:15PM	CytoSorbents Reports First Quarter 2020 Financial and Operational Results PR Newswire
May-04-20 07:08AM	CytoSorbents Promotes Vincent J. Capponi to President PR Newswire +9.07%
Apr-28-20 08:00AM	CytoSorbents to Report Q1 2020 Operating and Financial Results PR Newswire -8.28%
Apr-27-20 07:08AM	Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer PR Newswire +5.08%
Apr-20-20 06:58AM	Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery PR Newswire
Apr-15-20 07:00AM	New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on ECMO PR Newswire
Apr-13-20 03:31PM	Coronavirus update: 1.89 million cases worldwide, 118,304 deaths; and Trump attacks Dr. Fauci and the New York Times MarketWatch +21.40%
11:44AM	CytoSorbents Gains Emergency Authorization for Covid-19 Treatment TheStreet.com
10:06AM	CytoSorbents' stock jumps on FDA authorization for its device in COVID-19 patients MarketWatch
07:43AM	U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection PR Newswire
Apr-03-20 12:06PM	CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today PR Newswire -12.03%
Mar-31-20 07:08AM	CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care PR Newswire +17.66%
Mar-30-20 04:23PM	Cytosorbents Blood Purification Technology Could Play Important Role in Fighting COVID-19; Analyst Says Buy TipRanks +8.60%
Mar-25-20 07:19AM	CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama PR Newswire +29.28%
Mar-12-20 09:33AM	CytoSorbents Provides Update on CytoSorb and COVID-19 Coronavirus Activities PR Newswire -15.62%
Mar-05-20 04:15PM	CytoSorbents Announces 2019 Financial and Operational Results PR Newswire
02:45PM	CytoSorbents Corp. to Host Earnings Call ACCESSWIRE
Mar-02-20 07:00AM	CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits PR Newswire -5.47%
Feb-28-20 07:00AM	CytoSorb Shipment Arrives in Designated Mainland China Hospitals to Treat Cytokine Storm in Critically-ill Patients with COVID-19 Coronavirus Infection PR Newswire +14.86%
Feb-19-20 07:00AM	CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection PR Newswire +8.15%
Feb-05-20 07:51AM	CytoSorb Used Successfully to Help Treat Grade 4 Cytokine Release Syndrome Following CAR T-cell Immunotherapy in First Published Case Report PR Newswire
Feb-02-20 08:25AM	Analysts See 20% Upside to These 3 Strong Buy Tech Stocks TipRanks
Jan-29-20 07:25AM	CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U. PR Newswire
06:38AM	Introducing Cytosorbents (NASDAQ:CTSO), The Stock That Dropped 41% In The Last Five Years Simply Wall St.
Jan-28-20 07:01AM	CytoSorb, the Wuhan Coronavirus, and Cytokine Storm PR Newswire
Jan-22-20 06:30AM	CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin PR Newswire
Jan-14-20 09:30AM	CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter PR Newswire +5.57%
Jan-10-20 04:11PM	2 Healthcare Stocks Set to Rally into the New Year TipRanks
Jan-07-20 10:13AM	CytoSorbents to Present at Biotech Showcase 2020 PR Newswire
Dec-20-19 05:02PM	Is Cytosorbents Corporation (CTSO) A Good Stock To Buy? Insider Monkey
Dec-11-19 05:23AM	Trade Alert: The CEO, President & Director Of Cytosorbents Corporation (NASDAQ:CTSO), Phillip Chan, Has Just Spent US$59k Buying Shares Simply Wall St.
Dec-02-19 07:45AM	CytoSorbents to Present at the Piper Jaffray 31st Annual Healthcare Conference PR Newswire
Nov-25-19 07:00AM	CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study PR Newswire -7.36%
Nov-19-19 07:00AM	CytoSorbents to Present at the Three Part Advisors 2019 Southwest IDEAS Investor Conference PR Newswire
Nov-06-19 05:15PM	Dr. Eric Mortensen to Leave CytoSorbents At Year End PR Newswire -6.90%
Nov-05-19 04:15PM	CytoSorbents Reports Third Quarter 2019 Financial Results PR Newswire
05:52AM	Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt? Simply Wall St.
Nov-04-19 07:05AM	CytoSorbents Announces Additions to its International Clinical Team PR Newswire
Nov-01-19 07:15AM	CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom PR Newswire
Oct-30-19 07:30AM	CytoSorbents to Report Q3 2019 Operating and Financial Results PR Newswire

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol for treatment of severe hyperkalemia with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BLOCH KATHLEEN P.	Chief Financial Officer	Dec 31	Option Exercise	5.60	7,857	43,999	333,013	Jan 04 04:30 PM
Kraus Al	Director	Nov 10	Option Exercise	3.45	8,000	27,600	133,046	Nov 12 05:31 PM
Kraus Al	Director	Nov 10	Sale	8.00	8,000	64,000	125,046	Nov 12 05:31 PM
Jones Edward Raymond	Director	Aug 18	Option Exercise	3.35	4,000	13,400	78,800	Aug 20 04:10 PM
BLOCH KATHLEEN P.	Chief Financial Officer	Jul 31	Option Exercise	5.60	10,000	56,000	325,156	Aug 04 04:31 PM
Capponi Vincent	President and COO	May 05	Option Exercise	9.26	10,123	93,739	427,772	May 07 06:01 PM
Chan Phillip P.	Chief Executive Officer	May 05	Option Exercise	9.39	14,100	132,399	714,682	May 07 06:00 PM
Capponi Vincent	Chief Operating Officer	Apr 27	Option Exercise	2.88	10,000	28,750	427,649	Apr 29 04:15 PM
Capponi Vincent	Chief Operating Officer	Apr 27	Sale	10.00	10,000	100,000	417,649	Apr 29 04:15 PM
Capponi Vincent	Chief Operating Officer	Mar 10	Option Exercise	3.45	11,177	38,561	422,326	Mar 12 09:39 PM
Capponi Vincent	Chief Operating Officer	Mar 10	Sale	6.00	4,677	28,062	417,649	Mar 12 09:39 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience